A comparison study between doxorubicin and curcumin co-administration and co-loading in a smart niosomal formulation for MCF-7 breast cancer therapy

Basit Öğe Kaydı
dc.authoridZarepour, Atefeh/0000-0002-0347-5840
dc.authoridCordani, Marco/0000-0001-9342-4862
dc.authoridSaharkhiz, Shaghayegh/0009-0001-3377-2934
dc.authoridNasri, Negar/0000-0003-2845-6424
dc.authorwosidZarepour, Atefeh/AAH-9225-2020
dc.authorwosidCordani, Marco/ABF-4669-2021
dc.contributor.authorSaharkhiz, Shaghayegh
dc.contributor.authorZarepour, Atefeh
dc.contributor.authorNasri, Negar
dc.contributor.authorCordani, Marco
dc.contributor.authorZarrabi, Ali
dc.date.accessioned2024-05-19T14:46:12Z
dc.date.available2024-05-19T14:46:12Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractChemotherapy agents often exhibit limited effectiveness due to their fast elimination from the body and nontargeted delivery. Emerging nanomaterials as drug delivery carriers open new expectancy to overcome these limitations in current chemotherapeutic treatments. In this study, we introduce and evaluate a smart pHresponsive niosomal formulation capable of delivering Doxorubicin (DOX) and Curcumin (CUR) in both individually and co-loaded forms. In particular, drug-loaded niosomes were prepared using thin-film hydration method and then characterized via different physicochemical analyses. The pH responsivity of the carrier was assessed by performing a drug release study in three different pH conditions (4, 6.5, and 7.4). Finally, the anticancer efficacy of the therapeutic compounds was evaluated through the MTT assay. Our results showed spherical particles with a size of about 200 nm and -2 mV surface charge. Encapsulation efficiency (EE%) of the nanocarrier was about 77.06 % and 79.08 % for DOX and CUR, respectively. The release study confirmed the pH responsivity of the carrier. The MTT assay results revealed about 39 % and 43 % of cell deaths after treatment with cur-loaded and dox-loaded niosomes, which increased to 74 % and 79 % after co-administration and coloading forms of drugs, respectively, exhibiting increased anticancer efficacy by selectively delivering DOX and CUR individually or in combination. Overall, these findings suggest that our nanoformulation holds the potential as a targeted and highly effective approach for cancer management and therapy, overcoming the limitations of conventional chemotherapy drugs.en_US
dc.description.sponsorship1002-Short Term R&D Funding Program of The Scientific and Technological Research Council of Turkiye (TUBITAK) [221Z107]; Ramon y Cajal grant Spanish Ministry of Science and Innovation [RYC2021-031003-I]; Agencia Estatal de Investigacion (MCIN/AEI); European UnionNextGeneration (EU/PRTR); Spanish Ministry of Universities and Complutense University of Madriden_US
dc.description.sponsorshipAli Zarrabi acknowledges funding support from the 1002-Short Term R & D Funding Program of The Scientific and Technological Research Council of Turkiye (TUBITAK, Project No: 221Z107) . Marco Cordani is supported with a Ramon y Cajal grant (RYC2021-031003-I) from the Spanish Ministry of Science and Innovation, Agencia Estatal de Investigacion (MCIN/AEI/10.13039/501100011033) , and European UnionNextGeneration (EU/PRTR) . Marco Cordani acknowledges funding from Spanish Ministry of Universities and Complutense University of Madrid (Maria Zambrano grants for the requalification of the Spanish University System 2021-2023) .en_US
dc.identifier.doi10.1016/j.ejps.2023.106600
dc.identifier.issn0928-0987
dc.identifier.issn1879-0720
dc.identifier.pmid37802230en_US
dc.identifier.scopus2-s2.0-85173671143en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org10.1016/j.ejps.2023.106600
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5469
dc.identifier.volume191en_US
dc.identifier.wosWOS:001096457200001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofEuropean Journal of Pharmaceutical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectPh-Responsiveen_US
dc.subjectCo-Administrationen_US
dc.subjectDoxorubicinen_US
dc.subjectNiosomeen_US
dc.subjectCancer Therapyen_US
dc.titleA comparison study between doxorubicin and curcumin co-administration and co-loading in a smart niosomal formulation for MCF-7 breast cancer therapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu